Premium
Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma
Author(s) -
Mochel Mark C.,
Ming Michael E.,
Imadojemu Sotonye,
Gangadhar Tara C.,
Schuchter Lynn M.,
Elenitsas Rosalie,
Payne Aimee S.,
Chu Emily Y.
Publication year - 2016
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/cup.12735
Subject(s) - medicine , bullous pemphigoid , dermatitis herpetiformis , immune checkpoint , context (archaeology) , melanoma , vitiligo , immunology , pemphigoid , immune system , blockade , dermatology , disease , immunotherapy , cancer research , pathology , antibody , biology , paleontology , receptor
Therapeutic immune checkpoint blockade for metastatic melanoma has been associated with vitiligo, pruritus and morbilliform eruptions. Reports of other autoimmune skin disease in this setting are rare. We sought to expand the spectrum of cutaneous immune‐mediated effects related to immune checkpoint inhibitor therapy. In this report, we describe two unusual cutaneous reactions related to checkpoint inhibitor therapy, namely bullous pemphigoid ( BP ) and dermatitis herpetiformis. The development of BP and dermatitis herpetiformis in the context of checkpoint inhibitor therapy is consistent with previous investigations supporting the importance of effector and regulatory T cells in the pathogenesis of these diseases.